ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2084

ASP015K: A Novel JAK Inhibitor Demonstrated Potent Efficacy in Adjuvant-Induced Arthritis Model in Rats

Shunji Yamazaki1, Masamichi Inami1, Misato Ito1, Yasutomo Fujii1, Kaori Hanaoka1, Kaoru Yamagami1, Kenji Okuma1, Yoshiaki Morita1, Shohei Shirakami2, Takayuki Inoue2, Susumu Miyata3 and Yasuyuki Higashi1, 1Pharmacology Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 2Chemistry Research Labs, Astellas Pharma Inc., Tsukuba, Japan, 3Research Planning & Administration, Astellas Pharma Inc., Tsukuba, Japan

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, interleukins (IL), Janus kinase (JAK), pharmacology, rheumatoid arthritis (RA) and rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Janus kinase (JAK) family of enzymes plays a key role in cytokine signaling, which is involved in the pathogenic events of immune-mediated disorders such as rheumatoid arthritis (RA). The objectives of this study were to identify in vitro and in vivopharmacological profiles of a novel synthesized compound, ASP015K, and to evaluate its therapeutic potential in the treatment of RA patients using an experimental animal model.

Methods: In vitroenzyme inhibition assays were conducted against JAKs and tyrosine kinase 2 (TYK2) enzymes. Cell-based assays were also conducted to assess the selectivity of ASP015K for signaling via JAK1/JAK3 over JAK2/JAK2. JAK1/3 activation was evaluated by interleukin (IL)-2-stimulated T cell proliferation; JAK2/2 action was evaluated by erythropoietin (EPO)-stimulated erythroleukemia cell proliferation. In order to evaluate the potential efficacy of ASP015K to reduce clinical signs and symptoms of RA as well as disease progression, the reduction of paw swelling and ankle bone destruction in adjuvant-induced arthritic (AIA) rats were assessed after both prophylactic and therapeutic dosing regimens of ASP015K. Dunnett’s and Steel’s multiple comparison tests were used to compare ASP015K-treated groups with the control group of the paw volume and ankle bone destruction score, respectively.

Results: ASP015K inhibited JAK1, JAK2, JAK3 and TYK2 enzyme activities with IC50 values of 3.9, 5.0, 0.71 and 4.8 nM, respectively. ASP015K inhibited the IL-2-induced proliferation of human T cells with an IC50value of 18 nM. Moreover, ASP015K was 14-fold more potent against JAK1/3 than JAK2/2 on the basis of EPO-induced proliferation of human leukemia cells. This selectivity suggests that ASP015K has the potential to demonstrate JAK1/3-mediated immunomodulatory effects without the occurrence of JAK2-mediated hematopoietic effects. In rat AIA model, the hind paw volume gradually increased starting 10 days after adjuvant injection and ankle bone destruction was established by day 25, the end of the experiment. After once-daily oral administration of ASP015K 1 to 30 mg/kg in prophylactic dosing regimen, the increase in paw volume was significantly (p<0.05) decreased in a dose-dependent manner and was completely suppressed at the highest dose compared to control. Similar findings of dose-dependent reduction in ankle bone destruction score were observed. In therapeutic dosing regimens initiated after paw swelling was established, paw swelling and ankle bone destruction score was also suppressed in a dose-dependent manner.

Conclusion: Data from the current study demonstrates that ASP015K potently inhibits human JAK enzymes with moderate selectivity against JAK1/3 over JAK2/2, which may translate to less hematological side effects observed in the clinic such as anemia. In rat AIA model, ASP015K demonstrated a dose-dependent reduction in paw swelling and suppression of ankle bone destruction scores after both prophylactic and therapeutic dosing regimens. The data suggests that ASP015K has the potential to reduce clinical signs and symptoms as well as prevent disease progression in RA patients warranting further clinical investigation.


Disclosure:

S. Yamazaki,

Astellas Pharma Inc.,

3;

M. Inami,

Astellas Pharma Inc.,

3;

M. Ito,

Astellas Pharma Inc.,

3;

Y. Fujii,

Astellas Pharma Inc.,

3;

K. Hanaoka,

Astellas Pharma Inc.,

3;

K. Yamagami,

Astellas Pharma Inc.,

3;

K. Okuma,

Astellas Pharma Inc.,

3;

Y. Morita,

Astellas Pharma Inc.,

3;

S. Shirakami,

Astellas Pharma Inc.,

3;

T. Inoue,

Astellas Pharma Inc.,

3;

S. Miyata,

Astellas Pharma Inc.,

3;

Y. Higashi,

Astellas Pharma Inc.,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/asp015k-a-novel-jak-inhibitor-demonstrated-potent-efficacy-in-adjuvant-induced-arthritis-model-in-rats/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology